• Skip to primary navigation
  • Skip to main content

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • SAGES Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
      • SAGES Robotics Residents and Fellows Courses
      • MIS Fellows Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • Search
    • Search the SAGES Site
    • Guidelines Search
    • Video Search
    • Search Images
    • Search Abstracts
  • OWLS/FLS
  • Login
You are here: Home / Abstracts / Plasma Soluble Vascular Adhesion Molecule-1 Levels Are Persistently Elevated During the First Month After Colorectal Cancer Resection

Plasma Soluble Vascular Adhesion Molecule-1 Levels Are Persistently Elevated During the First Month After Colorectal Cancer Resection

Introduction: Human Vascular Cell Adhesion Molecule -1(VCAM1) is a 110 kDa transmembrane glycoprotein expressed in vascular endothelial cells (EC), neurons, fibroblast and macrophages. Expression is regulated by inflammatory cytokines such as IL-1, TNFalpha, IL-4 and IL-13. Soluble VCAM-1 (sVCAM-1) is made when the extracellular part of VCAM-1 is shed from the cell surface into the circulation. The ligands for both are the alpha-4integrins. Ligand binding to EC bound VCAM-1 promotes leukocyte recruitment and extravasation whereas binding to sVCAM-1 promotes neovascularization, critical to both wound repair and tumor growth. Increased serum levels of sVCAM-1 has been found in patients with breast, ovarian and gastric cancers, however, the impact of surgery on sVCAM levels has not been determined in the cancer setting. This study’s purpose was to evaluate plasma levels of sVCAM-1 during the first month after minimally invasive colorectal resections (MICR).
Methods: Clinical, operative and demographic data was collected. Blood samples were taken preoperatively (PO) and postoperative day (POD) 1 and 3 in all patients. In a subset, sample(s) were taken 2-8 weeks after surgery. Late samples after POD 7 were bundled into 7 day time blocks which were considered as single time points. Plasma sVCAM-1 levels were analyzed in duplicate via ELISA and results reported as mean ±SD. The t-test was used for data analysis (significance<0.008 after Bonferroni correction)
Results: A total of 91 colorectal cancer (CRC) patients(pts) were studied (26% rectal, 74% colon). The MICR’s were laparoscopic-assisted in 60% and hand-assisted in 40%; the overall mean incision length was 7.4 ± 3.3 cm and mean length of stay was 6.0 ±; 2.2 days. The mean sVCAM-1 levels (ng /ml) were significantly higher on POD1 (903.5± 291.6 , p<0.001) and POD3 (976.9± 270.4, p<0.001) vs PO levels (808.9±233.0). Levels remained significantly elevated for the POD7-13 (959.8 ± 231.9; n=49, p< 0.001), POD14-20 (949.4± 309.8;n=30,p=0.004), POD 21-27 (816.4± 176.6;n=23,p=.001) and POD28+ (912.8± 261.2;n=53,p<0.001) time blocks.
Discussion: For the vast majority of proteins 1-3 day plasma level changes are noted post MICR. Plasma sVCAM-1 levels are elevated for over 1 month. Similarly persistent increases were noted for VEGF, Angiopetin2 and PLGF. The likely source of these proangiogenic proteins are the wounds. This environment may promote tumor growth post MICR inpts with residual cancer. Further study is needed to determine the duration and significance of this effect. Anti-cancer treatment perioperatively may be warranted.


Session: Poster

Program Number: P142

View Poster

49


  • Foundation
  • SAGES.TV
  • MyCME
  • Educational Activities

Copyright © 2025 Society of American Gastrointestinal and Endoscopic Surgeons